

OUR PIPELINE

Takeda Oncology is working to discover and develop innovative new therapies that will make a difference in patients' lives.

The molecules in our development pipeline are ordered by their phase in the clinical development process, and within each phase molecules are ordered alphabetically. Phase 1 trials are conducted to determine proper dosing, while Phase 2 and 3 Studies determine the efficacy, side effects and safety of the therapies being researched.

Certain molecules may be under study for more than one disease area. Click on the arrows to learn more about each one.

PROGRAM	PHASE	PHASE 1	PHASE 2	PHASE 3
BRENTUXIMAB VEDOTIN¹		●	●	●
DESCRIPTION CD30 Antibody Drug Conjugate	DISEASE(S) UNDER INVESTIGATION Hodgkin Lymphoma, Cutaneous T-Cell Lymphoma, Mature T-Cell Lymphoma, Anaplastic Large Cell Lymphoma			
BRIGATINIB		●	●	●
DESCRIPTION ALK Inhibitor	DISEASE(S) UNDER INVESTIGATION Non-small Cell Lung Cancer			
IXAZOMIB		●	●	●
DESCRIPTION Proteasome Inhibitor	DISEASE(S) UNDER INVESTIGATION Multiple Myeloma, Amyloidosis			

PROGRAM	PHASE	PHASE 1	PHASE 2	PHASE 3
---------	-------	---------	---------	---------

LEUPRORELIN ACETATE²



DESCRIPTION
LH-RH Agonist

DISEASE(S) UNDER INVESTIGATION
Prostate Cancer, Breast Cancer, new formulation

PANITUMUMAB³



DESCRIPTION
Anti-EGFR Antibody

DISEASE(S) UNDER INVESTIGATION
Colorectal Cancer

PEVONEDISTAT



DESCRIPTION
Nedd8-Activating Enzyme Inhibitor

DISEASE(S) UNDER INVESTIGATION
High-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Low-Blast Acute Myelogenous Leukemia

PEVONEDISTAT



DESCRIPTION
Nedd8-Activating Enzyme Inhibitor

DISEASE(S) UNDER INVESTIGATION
Solid Tumors

PROGRAM	PHASE	PHASE 1	PHASE 2	PHASE 3
---------	-------	---------	---------	---------

PONATINIB⁴



DESCRIPTION
BCR-ABL Inhibitor

DISEASE(S) UNDER INVESTIGATION
Chronic Myeloid Leukemia

PONATINIB⁴



DESCRIPTION
BCR-ABL Inhibitor

DISEASE(S) UNDER INVESTIGATION
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

SAPANISERTIB (TAK-228)



DESCRIPTION
TORC1/TORC2 Inhibitor

DISEASE(S) UNDER INVESTIGATION
Breast Cancer, Renal Cell Carcinoma, Endometrial Cancer

TAK-117



DESCRIPTION
PI3K Alpha Inhibitor

DISEASE(S) UNDER INVESTIGATION
Renal Cell Carcinoma

PROGRAM	PHASE	PHASE 1	PHASE 2	PHASE 3
---------	-------	---------	---------	---------

TAK-659



DESCRIPTION
SYK/FLT-3 Inhibitor

DISEASE(S) UNDER INVESTIGATION
Lymphoma, Acute Myelogenous Leukemia

TAK-659



DESCRIPTION
SYK/FLT-3 Inhibitor

DISEASE(S) UNDER INVESTIGATION
Solid Tumors

TAK-931



DESCRIPTION
CDC7 Inhibitor

DISEASE(S) UNDER INVESTIGATION
Pancreatic Cancer, Colorectal Cancer

VEDOLIZUMAB



DESCRIPTION
Anti- α 4 β 7 Antibody

DISEASE(S) UNDER INVESTIGATION
Graft versus Host Disease

PROGRAM

PHASE

PHASE 1

PHASE 2

PHASE 3

TAK-243



DESCRIPTION

Ubiquitin-Activating Enzyme Inhibitor

DISEASE(S) UNDER INVESTIGATION

Solid Tumors

TAK-522 (XMT-1522)⁵



DESCRIPTION

HER2 Dolaflexin Antibody Drug Conjugate

DISEASE(S) UNDER INVESTIGATION

Breast Cancer

TAK-573



DESCRIPTION

CD38-targeted IgG4 fused with attenuated IFN α

DISEASE(S) UNDER INVESTIGATION

Multiple Myeloma

TAK-580



DESCRIPTION

Pan-Raf Inhibitor

DISEASE(S) UNDER INVESTIGATION

Solid Tumors

PROGRAM	PHASE	PHASE 1	PHASE 2	PHASE 3
---------	-------	---------	---------	---------

TAK-788 (AP32788)



<p>DESCRIPTION EGFR/HER2 Inhibitor</p>	<p>DISEASE(S) UNDER INVESTIGATION Non-small Cell Lung Cancer</p>
---	---

CABOZANTINIB²

Development in Preparation

<p>DESCRIPTION MET, VEGF, AXL and RET Inhibitor</p>	<p>DISEASE(S) UNDER INVESTIGATION Renal Cell Carcinoma</p>
--	---

NIRAPARIB⁶

Development in Preparation

<p>DESCRIPTION PARP Inhibitor</p>	<p>DISEASE(S) UNDER INVESTIGATION Solid Tumors</p>
--	---

Last updated 2017-10-31

All programs have Global Development Rights unless otherwise noted.

1 Brentuximab vedotin is co-developed by Takeda and Seattle Genetics, Inc. 2 Japan Only. 3 Japan Only. In-Licensed. 4 Takeda shares development rights with Incyte (Europe, Turkey and Israel) and Otsuka (Asia Pacific territories). 5 Ex-US, Ex-Canada. TAK-522 (XMT-1522) is co-developed by Takeda and Mersana Therapeutics, Inc. 6 Niraparib is being developed under a licensing agreement with Tesaro, Inc. for all tumor types in Japan and all tumor types excluding prostate cancer in South Korea, Taiwan, Russia and Australia.



ONCOLOGY

©2018 Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
All rights reserved. 04/18